• The financing round is led by Alta Life Sciences Spain I FCR, a vehicle managed by Altamar Private Equity SGIIC. Existing investors including Institut Català de Finances (ICF) have also participated in the financing. • Inbiomotion is in advanced stage of development of a single gene-based test for predicting response to bisphosphonates in breast cancer adjuvant setting and prevent metastasis. • The capital increase is intended to complete regulatory…
Five neurology experts join CNS specialist’s scientific advisory board to support clinical trial development of disease modifying drug candidates Barcelona, Spain, January 11, 2021 – Accure Therapeutics, a private translational R&D engine at clinical stage in the Central Nervous System (CNS) field, today announces the appointment of five world-class neurology experts to its scientific advisory board. They will help boost innovation and advocate for Accure Therapeutics, as the company drives…
Peptomyc Board of Directors appoints Giacomo Di Nepi as Chairman of the Board
Sanifit to Participate in the 2021 ICR Conference
Peptomyc steps forward as a Clinical Stage Biotech company
binx health receives EUA authorizing At-Home COVID-19 sample collection by universities and employers
Subgroup Analyses from Sanifit’s CaLIPSO Phase 2b Clinical Study Published in Kidney International Reports
This investment will help Peptomyc lead its drug candidate OMO103 into clinical phase I/II as a treatment for solid tumors Barcelona, Spain, December 15, 2020 – Peptomyc S.L., a biotech company specialized in the development of protein and peptide therapeutics for cancer treatment, has just announced the completion of an equity financing round of EUR 11.4 million. The company is focused on the development of a new generation of cell penetrating…
Founded in 2019 by Jordi Carrera and Rafel Bru former founders of STAT-Dx, a company sold to QIAGEN in 2018 for 191 million dollars. Round led by Alta Life Sciences and Kurma Partners (France) and supported by Axis Participaciones Empresariales (ICO) and Sofimac Innovation (France). Financing to validate the technology and build the first units. Barcelona, 7 July 2020.- DeepUll announced today the closing of a 3.5 million…
Breakthrough approach to developing first-in-class treatments for metastatic cancer patients Financing to progress lead candidate to proof of clinical efficacy Supported by strong European investor syndicate including Alta Life Sciences, Asabys Partners, Bpifrance – InnoBio 2, Fund+ and Ysios Capital Barcelona, Spain, June 16th 2020: Ona Therapeutics, which is focused on the discovery and development of therapeutic biologics to treat metastatic cancer, announces today the closing of a €30 million…
